Vidzemes bernu veselibas centrs Apelsins SIA
- Address
- lock Available on a paid plan
Vidzemes bernu veselibas centrs Apelsins SIA - Pediatric Infectious Disease Research
Vidzemes bernu veselibas centrs Apelsins SIA is a specialized pediatric health center dedicated to advancing clinical research in childhood infectious diseases. The center focuses on evaluating innovative preventive therapies and vaccines for vulnerable infant and toddler populations, with particular emphasis on respiratory health and immunization strategies.
- Safety and tolerability assessment of novel mRNA vaccine candidates in infants and young children
- Acute lower respiratory infection prevention and management in pediatric populations
- Immunogenicity studies evaluating vaccine responses in children aged 5 months to 24 months
The center demonstrates expertise in conducting complex early-phase vaccine trials in very young children, requiring specialized pediatric research capabilities and careful monitoring protocols. Their work contributes to the development of preventive interventions for acute respiratory infections, which remain a significant health concern in infants and toddlers worldwide.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 80 other sites in Latvia
Therapeutic Area Benchmark — Latvia
Select a therapeutic area to compare against other sites in Latvia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Latvia
Market Share
Country: Latvia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vidzemes bernu veselibas centrs Apelsins SIA
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 months to < 24 months | Moderna Inc. | Phase I | Not Recruiting | May 2024 | Dec 2024 |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| MRNA-1345 | 1 | Unknown | 2024-05-28 | 2024-05-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.